IRIS
MARABOTTO, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.127
AS - Asia 1.532
NA - Nord America 913
SA - Sud America 135
AF - Africa 36
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.750
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.782
US - Stati Uniti d'America 868
SG - Singapore 612
CN - Cina 430
VN - Vietnam 288
FR - Francia 127
BR - Brasile 84
HK - Hong Kong 57
FI - Finlandia 56
DE - Germania 36
GB - Regno Unito 36
IN - India 30
JP - Giappone 28
AR - Argentina 24
MX - Messico 20
CA - Canada 18
BD - Bangladesh 14
NL - Olanda 12
IQ - Iraq 11
ES - Italia 10
UA - Ucraina 10
ID - Indonesia 9
PH - Filippine 9
RU - Federazione Russa 9
IE - Irlanda 8
CH - Svizzera 7
CL - Cile 7
EC - Ecuador 7
JO - Giordania 7
ZA - Sudafrica 6
KE - Kenya 5
PL - Polonia 5
SA - Arabia Saudita 5
AZ - Azerbaigian 4
CO - Colombia 4
EG - Egitto 4
LT - Lituania 4
NP - Nepal 4
TH - Thailandia 4
TR - Turchia 4
UZ - Uzbekistan 4
BA - Bosnia-Erzegovina 3
ET - Etiopia 3
MA - Marocco 3
PE - Perù 3
PT - Portogallo 3
RS - Serbia 3
SN - Senegal 3
VE - Venezuela 3
AT - Austria 2
AU - Australia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
FJ - Figi 2
JM - Giamaica 2
LB - Libano 2
LV - Lettonia 2
MY - Malesia 2
PK - Pakistan 2
PY - Paraguay 2
RO - Romania 2
SE - Svezia 2
SI - Slovenia 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
IL - Israele 1
KH - Cambogia 1
LC - Santa Lucia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
NC - Nuova Caledonia 1
TG - Togo 1
UG - Uganda 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 13.750
Salva come PNG Salva come JPEG
Città #
Genova 5.006
Genoa 3.912
Vado Ligure 897
Rapallo 830
Singapore 255
San Jose 254
Ashburn 183
Lauterbourg 116
Council Bluffs 110
Ho Chi Minh City 84
Hanoi 72
Beijing 66
Hong Kong 55
New York 52
Helsinki 45
Tokyo 27
Frankfurt am Main 26
Orem 23
Bordighera 21
Los Angeles 20
Santa Clara 20
Milan 18
Mexico City 15
Da Nang 14
Chicago 11
Lappeenranta 11
Haiphong 10
St Louis 10
São Paulo 10
Amsterdam 9
Montreal 9
Dublin 8
Mumbai 8
Tianjin 8
Amman 7
Chennai 7
Dallas 7
Kyiv 7
London 7
Rome 7
Zurich 7
Bologna 6
Manchester 6
Poplar 6
Shanghai 6
Atlanta 5
Buenos Aires 5
Cardiff 5
Guangzhou 5
Toronto 5
Warsaw 5
Baghdad 4
Nairobi 4
Naples 4
Tampa 4
Tashkent 4
Thái Bình 4
Addis Ababa 3
Baku 3
Bangkok 3
Belgrade 3
Biên Hòa 3
Bình Phước 3
Bắc Ninh 3
Cairo 3
Can Tho 3
Concepción 3
Curitiba 3
Dakar 3
Hải Dương 3
Milwaukee 3
Modena 3
Ninh Bình 3
Padua 3
Phoenix 3
Quảng Ngãi 3
Quận Ba 3
Rio de Janeiro 3
Riyadh 3
San Francisco 3
Asunción 2
Basra 2
Berlin 2
Bogotá 2
Borgosesia 2
Brooklyn 2
Brugherio 2
Buffalo 2
Cachoeira do Sul 2
Cebu City 2
City of London 2
Dehradun 2
Delhi 2
Denver 2
Des Moines 2
Duque de Caxias 2
Elk Grove Village 2
Erbil 2
Florence 2
Greensboro 2
Totale 12.451
Salva come PNG Salva come JPEG
Nome #
Proton pump inhibitors: use and misuse in the clinical setting 235
Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers 216
Advancements in the use of manometry and impedance testing for esophageal functional disorders 203
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 202
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 199
A safety review of proton pump inhibitors to treat acid-related digestive diseases 195
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 195
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 192
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 189
Measurement of oro-caecal transit time by magnetic resonance imaging. 184
Drugs for improving esophageal mucosa defense: Where are we now and where are we going? 183
The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. 182
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 171
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 170
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 170
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 167
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 167
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 166
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 166
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 158
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 157
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 157
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 156
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 155
Optimal management of constipation associated with irritable bowel syndrome. 152
Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602]. 151
The appropriate use of proton-pump inhibitors 149
Epidemiology and natural history of gastroesophageal reflux disease 145
The natural history of gastro-esophageal reflux disease: A comprehensive review 144
Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity 141
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. 140
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 135
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 134
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 133
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 132
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 132
Relevance of measuring substances in bronchoalveolar lavage fluid for detecting aspiration-associated extraesophageal reflux disease 131
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn 131
Pathophysiological studies are mandatory to understand the benefit of proton pump inhibitors in patients with idiopathic pulmonary fibrosis 129
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 129
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 128
Overweight is a risk factor for both erosive and non-erosive reflux disease. 127
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 125
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 122
Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD 121
Esophageal motility abnormalities in gastroesophageal reflux disease 121
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 118
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 116
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 115
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 114
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 113
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 111
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 111
Vonoprazan fumarate for the management of acid-related diseases 110
Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients with Eosinophilic Esophagitis 110
Review article – esophageal reflux hypersensitivity: Non-GERD or still GERD? 109
Updates in the field of non-esophageal gastroesophageal reflux disorder 108
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 108
Diabetes Medications and Risk of Hepatocellular Carcinoma 107
Effects of bariatric surgery on the esophagus 106
Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance 105
Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis. 100
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 97
Can High-Frequency Intraoral Ultrasound Predict Histological Risk Factors in Oral Squamous Cell Carcinoma? A Preliminary Experience 95
The Lyon Consensus: Does it differ from the previous ones? 94
The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication 91
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 91
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring 90
Pharmacotherapies in eosinophilic esophagitis: state of the art 89
Esophageal motor disorders across ages: A retrospective multicentric analysis 88
Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis 88
Nonacid Reflux Is Able to Determine Microscopic Esophagitis in Non-Erosive Reflux Disease (NERD) Patients. 88
Expression of Epidermal Growth Factor Receptor in patients with gastro-oesophageal reflux disease and in those with Systemic Sclerosis 88
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis – Definition, Clinical Presentation and Diagnosis 87
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 84
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 83
null 83
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis–Current Treatment and Monitoring 82
Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach 82
Prevention Strategies for Esophageal Cancer—An Expert Review 80
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 80
Expression of Epidermal Growth Factor receptor (EGFR) in Systemic Sclerosis patients (SSc) and Gastro-oesophageal Reflux Disease (GORD) 79
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 79
Evaluation of the pathophysiological association between the GERD and OSAS: Esophageal pH-monitoring results beyond Lyon criteria 78
Esophageal dysmotility in patients with eosinophilic esophagitis: pathogenesis, assessment tools, manometric characteristics, and clinical implications 77
Food Intolerances, Food Allergies and IBS: Lights and Shadows 76
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 76
Clopidogrel-Induced Eosinophilic Colitis 75
Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high‐resolution manometry studies 75
The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions 74
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 74
From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease 73
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 73
Presence of basal cell hyperplasia and dilatation of intercellular spaces and their association with baseline impedance values in patients with positive symptom association despite normal acid exposure further supports their role in symptoms generation in NERD 72
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 72
Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients 72
Endoscopic Management of Eosinophilic Esophagitis: A Narrative Review on Diagnosis and Treatment 70
Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults 68
COVID‐19 and liver disease: not all evil comes to harm 68
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis 67
Totale 12.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.587
article - articoli 48.094
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 493
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.174
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021249 0 0 0 0 0 0 0 0 0 105 66 78
2021/20221.036 102 27 67 95 33 104 32 229 66 121 36 124
2022/20231.013 105 100 19 87 177 131 6 85 177 5 110 11
2023/2024726 25 74 8 100 54 124 61 21 32 36 64 127
2024/20252.467 136 138 116 164 266 295 200 398 117 96 272 269
2025/20264.791 555 178 492 522 567 422 756 278 456 565 0 0
Totale 14.260